Vitestro

Executive Summary

Vitestro has developed Aletta®, the world's first Autonomous Robotic Phlebotomy Device (ARPD), addressing a critical bottleneck in healthcare: manual blood draws. By automating the diagnostic blood collection process, Aletta promises to improve standardization, patient experience, and operational efficiency in hospitals and laboratories. Founded in 2017 in Utrecht, Netherlands, the company has advanced through clinical validation and collaborations with leading healthcare institutions. The technology targets a large addressable market, as billions of blood draws are performed annually worldwide. With an aging population and growing demand for diagnostics, Vitestro's solution could alleviate staffing shortages and reduce variability in blood collection. The company's progress in clinical settings positions it for potential commercialization in the near term.

Upcoming Catalysts (preview)

• Q2 2027CE Mark or FDA Regulatory Approval for Aletta70% success
• Q4 2027Commercial Launch in European Hospitals60% success
• Q3 2026Series B or C Funding Round80% success